Caitlyn L. Miller

发表

Design of a mucin-selective protease for targeted degradation of cancer-associated mucins

C. Bertozzi, V. Weaver, B. George, 2022, bioRxiv.

Lysosome Targeting Chimeras (LYTACs) That Engage a Liver-Specific Asialoglycoprotein Receptor for Targeted Protein Degradation

C. Bertozzi, J. Cochran, N. Riley, 2020 .

Targeted glycan degradation potentiates the anticancer immune response in vivo

C. Bertozzi, Elliot C Woods, H. Läubli, 2020, Nature Chemical Biology.

LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation

C. Bertozzi, J. Cochran, N. Riley, 2021, Nature Chemical Biology.

Systemic delivery of a targeted synthetic immunostimulant transforms the immune landscape for effective tumor regression.

D. Czerwinski, C. Bertozzi, J. Cochran, 2021, Cell chemical biology.

An engineered antibody binds a distinct epitope and is a potent inhibitor of murine and human VISTA

Ryan L. Kelly, Louai Labanieh, J. Cochran, 2020, Scientific Reports.

Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma.

J. Sarkaria, F. White, J. Eckel-Passow, 2021, Neuro-oncology.

Targeting the tetraspanin CD81 reduces cancer invasion and metastasis

S. Jeffrey, S. Levy, F. Vences-Catalán, 2021, Proceedings of the National Academy of Sciences.

Design of a mucin-selective protease for targeted degradation of cancer-associated mucins

C. Bertozzi, V. Weaver, B. George, 2023, Nature biotechnology.